Treatment-resistant prurigo nodularis

"Treatment-resistant prurigo nodularis." Clinical, Cosmetic and Investigational Dermatology, , pp. 345–346

Disclosure

Dr Steven Feldman is a speaker for Janssen and Taro. He is a consultant and speaker for Galderma, Stiefel/GlaxoSmithKline, Abbott Labs, Leo Pharma Inc. Dr Feldman has received grants from Galderma, Janssen, Abbott Labs, Amgen, Stiefel/GlaxoSmithKline, Celgene and Anacor. He is a consultant for Amgen, Baxter, Caremark, Gerson Lehrman Group, Guidepoint Global, Hanall Pharmaceutical Co. Ltd, Kikaku, Lilly, Merck & Co. Inc., Merz Pharmaceuticals, Mylan, Novartis Pharmaceuticals, Pfizer Inc, Qurient, Suncare Research and Xenoport. He is on an advisory board for Pfizer Inc. Dr Feldman is the founder and holds stock in Causa Research and holds stock and is majority owner in Medical Quality Enhancement Corporation. He receives Royalties from UpToDate and Xlibris. Dr Steven Feldman reports personal fees from Menlo, personal fees from Sanofi, grants, personal fees from Pfizer, outside the submitted work; and has received research, speaking and/or consulting support from a variety of companies including Galderma, GSK/Stiefel, Almirall, Alvotech, Leo Pharma, BMS, Boehringer Ingelheim, Mylan, Celgene, Pfizer, Ortho Dermatology, Abbvie, Samsung, Janssen, Lilly, Menlo, Merck, Novartis, Regeneron, Sanofi, Novan, Qurient, National Biological Corporation, Caremark, Advance Medical, Sun Pharma, Suncare Research, Informa, UpToDate and National Psoriasis Foundation. Dr Steven Feldman also consults for others through Guidepoint Global, Gerson Lehrman and other consulting organizations. Dr Steven Feldman is founder and majority owner of www.DrScore.com. Dr Steven Feldman is a founder and part owner of Causa Research, a company dedicated to enhancing patients’ adherence to treatment. The authors report no other conflicts of interest in this communication.